Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK.

Cancer Discov. 2019 Oct 1. pii: CD-19-0555. doi: 10.1158/2159-8290.CD-19-0555. [Epub ahead of print]

PMID:
31575541
2.

Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma.

Lam JH, Ng HHM, Lim CJ, Sim XN, Malavasi F, Li H, Loh JJH, Sabai K, Kim JK, Ong CCH, Loh T, Leow WQ, Choo SP, Toh HC, Lee SY, Chan CY, Chew V, Lim TS, Yeong J, Lim TKH.

Front Immunol. 2019 Sep 4;10:2093. doi: 10.3389/fimmu.2019.02093. eCollection 2019.

3.

The effect of diagnosis-related group payment system on the quality of medical care for pelvic organ prolapse in Korean tertiary hospitals.

Jeon MJ, Choo SP, Kwak YH, Kim DW, Kim EH.

PLoS One. 2019 Aug 20;14(8):e0220895. doi: 10.1371/journal.pone.0220895. eCollection 2019.

4.

Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series.

Alsuwaigh R, Lee J, Chan G, Chee CE, Choo SP.

J Immunother Cancer. 2019 Jun 27;7(1):162. doi: 10.1186/s40425-019-0637-6.

5.

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.

Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Cruz CD, Kudo M.

J Hepatol. 2019 Sep;71(3):543-552. doi: 10.1016/j.jhep.2019.05.014. Epub 2019 Jun 7.

6.

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q.

Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x.

7.

Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.

Wong DJ, Lee J, Choo SP, Thng CH, Hennedige T.

Immunotherapy. 2019 Feb;11(3):167-175. doi: 10.2217/imt-2018-0126.

PMID:
30730278
8.

Benefits and risks of induction of labor at 39 or more weeks in uncomplicated nulliparous women: a retrospective, observational study.

Kim HI, Choo SP, Han SW, Kim EH.

Obstet Gynecol Sci. 2019 Jan;62(1):19-26. doi: 10.5468/ogs.2019.62.1.19. Epub 2018 Nov 28.

9.

Cancer Supportive and Survivorship Care in Singapore: Current Challenges and Future Outlook.

Loh KW, Ng T, Choo SP, Saw HM, Mahendran R, Tan C, Chang GCY, Ong YJ, Yee ACP, Chan A, Soo KC.

J Glob Oncol. 2018 Sep;4:1-8. doi: 10.1200/JGO.17.00117.

10.

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.

Yong WP, Rha SY, Tan IB, Choo SP, Syn NL, Koh V, Tan SH, Asuncion BR, Sundar R, So JB, Shabbir A, Tan CS, Kim HS, Jung M, Chung HC, Ng MCH, Tai DW, Lee MH, Wu J, Yeoh KG, Tan P; Singapore Gastric Cancer Consortium (SGCC).

Clin Cancer Res. 2018 Nov 1;24(21):5272-5281. doi: 10.1158/1078-0432.CCR-18-0193. Epub 2018 Jul 25.

PMID:
30045931
11.

Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence.

Koh YX, Tan HL, Lye WK, Kam JH, Chiow AKH, Tan SS, Choo SP, Chung AYF, Goh BKP.

World J Hepatol. 2018 Jun 27;10(6):433-447. doi: 10.4254/wjh.v10.i6.433.

12.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.

Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM.

Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. doi: 10.1158/1078-0432.CCR-17-3588. Epub 2018 Jun 27.

13.

Metastatic gastric cancer: Does the site of metastasis make a difference?

Tan HL, Chia CS, Tan GHC, Choo SP, Tai DW, Chua CWL, Ng MCH, Soo KC, Teo MCC.

Asia Pac J Clin Oncol. 2019 Feb;15(1):10-17. doi: 10.1111/ajco.13025. Epub 2018 Jun 19.

PMID:
29920947
14.

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.

Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han HS, Bae SH, Yoon HK, Lee RC, Hung CF, Peng CY, Liang PC, Bartlett A, Kok KYY, Thng CH, Low AS, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group.

J Clin Oncol. 2018 Jul 1;36(19):1913-1921. doi: 10.1200/JCO.2017.76.0892. Epub 2018 Mar 2.

PMID:
29498924
15.

Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma.

Teo JY, Allen JC, Ng DCE, Abdul Latiff JB, Choo SP, Tai DW, Low ASC, Cheah FK, Chang JPE, Kam JH, Lee VTW, Chung AYF, Chan CY, Chow PKH, Goh BKP.

Surgery. 2018 May;163(5):1008-1013. doi: 10.1016/j.surg.2017.10.014. Epub 2018 Jan 3.

PMID:
29306542
16.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

17.

Comparison of health state values derived from patients and individuals from the general population.

Gandhi M, Tan RS, Ng R, Choo SP, Chia WK, Toh CK, Lam C, Lee PT, Latt NKZ, Rand-Hendriksen K, Cheung YB, Luo N.

Qual Life Res. 2017 Dec;26(12):3353-3363. doi: 10.1007/s11136-017-1683-5. Epub 2017 Aug 14.

PMID:
28808840
18.

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S, Mok ZY, Koh KX, Toh HC, Koo WH, Loh M, Ng RCH, Choo SP, Soong RCT.

JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269.

19.

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.

Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AST, Lim TH, Tan J, Loh JL, McPherson JR, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow PK, Chung AYF, Ooi LLPJ, Lim KH, Dima S, Duda DG, Popescu I, Broet P, Hsieh SY, Yu MC, Scarpa A, Lai J, Luo DX, Carvalho AL, Vettore AL, Rhee H, Park YN, Alexandrov LB, Gordân R, Rozen SG, Shibata T, Pairojkul C, Teh BT, Tan P.

Cancer Discov. 2017 Oct;7(10):1116-1135. doi: 10.1158/2159-8290.CD-17-0368. Epub 2017 Jun 30.

20.

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I.

Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.

PMID:
28434648
21.

Coriolus versicolor (Yunzhi) Use as Therapy in Advanced Hepatocellular Carcinoma Patients with Poor Liver Function or Who Are Unfit for Standard Therapy.

Chay WY, Tham CK, Toh HC, Lim HY, Tan CK, Lim C, Wang WW, Choo SP.

J Altern Complement Med. 2017 Aug;23(8):648-652. doi: 10.1089/acm.2016.0136. Epub 2017 Apr 4.

PMID:
28375640
22.

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).

Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartono S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP.

Ann Oncol. 2018 Feb 1;29(2):526. doi: 10.1093/annonc/mdx060. No abstract available.

PMID:
28368515
23.

Gastric peritoneal carcinomatosis - a retrospective review.

Tan HL, Chia CS, Tan GH, Choo SP, Tai DW, Chua CW, Ng MC, Soo KC, Teo MC.

World J Gastrointest Oncol. 2017 Mar 15;9(3):121-128. doi: 10.4251/wjgo.v9.i3.121.

24.

The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma.

Zhai W, Lim TK, Zhang T, Phang ST, Tiang Z, Guan P, Ng MH, Lim JQ, Yao F, Li Z, Ng PY, Yan J, Goh BK, Chung AY, Choo SP, Khor CC, Soon WW, Sung KW, Foo RS, Chow PK.

Nat Commun. 2017 Feb 27;8:4565. doi: 10.1038/ncomms14565.

25.

Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery.

Ng SB, Chua C, Ng M, Gan A, Poon PS, Teo M, Fu C, Leow WQ, Lim KH, Chung A, Koo SL, Choo SP, Ho D, Rozen S, Tan P, Wong M, Burkholder WF, Tan IB.

Sci Rep. 2017 Jan 19;7:40737. doi: 10.1038/srep40737.

26.

201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre.

Tan G, Chia C, Kumar M, Choo SP, Chia J, Tham CK, Chua C, Soo KC, Teo M.

Int J Hyperthermia. 2017 May;33(3):288-294. doi: 10.1080/02656736.2016.1262064. Epub 2016 Dec 14.

PMID:
27855557
27.

Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.

Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK; Asia-Pacific Hepatocellular Carcinoma Trials Group.

BMC Cancer. 2016 Nov 7;16(1):856.

28.

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).

Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartano S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP.

Ann Oncol. 2016 Dec;27(12):2210-2215. doi: 10.1093/annonc/mdw415. Epub 2016 Sep 28. Erratum in: Ann Oncol. 2018 Feb 1;29(2):526.

PMID:
27681866
29.

Comparison of hepatocellular carcinoma in Eastern versus Western populations.

Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX.

Cancer. 2016 Nov 15;122(22):3430-3446. doi: 10.1002/cncr.30237. Epub 2016 Sep 13. Review.

30.

Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma.

Chng KR, Chan SH, Ng AHQ, Li C, Jusakul A, Bertrand D, Wilm A, Choo SP, Tan DMY, Lim KH, Soetinko R, Ong CK, Duda DG, Dima S, Popescu I, Wongkham C, Feng Z, Yeoh KG, Teh BT, Yongvanit P, Wongkham S, Bhudhisawasdi V, Khuntikeo N, Tan P, Pairojkul C, Ngeow J, Nagarajan N.

EBioMedicine. 2016 Jun;8:195-202. doi: 10.1016/j.ebiom.2016.04.034. Epub 2016 May 6.

31.

National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma.

Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH.

Liver Cancer. 2016 Apr;5(2):97-106. doi: 10.1159/000367759. Epub 2016 Mar 17.

32.

Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.

Chong DQ, Manalo M, Imperial M, Teo P, Yong G, Ng M, Tan IB, Choo SP, Chua C.

Asia Pac J Clin Oncol. 2016 Sep;12(3):275-83. doi: 10.1111/ajco.12496. Epub 2016 Apr 14.

PMID:
27075236
33.

A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.

Teo JY, Allen JC Jr, Ng DC, Choo SP, Tai DW, Chang JP, Cheah FK, Chow PK, Goh BK.

HPB (Oxford). 2016 Jan;18(1):7-12. doi: 10.1016/j.hpb.2015.07.002. Epub 2015 Dec 11. Review.

34.

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma.

Lee JJX, Chan JJ, Choo SP.

Diseases. 2015 Oct 28;3(4):306-324. doi: 10.3390/diseases3040306. Review.

35.

A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.

Teo JY, Allen JC Jr, Ng DC, Choo SP, Tai DW, Chang JP, Cheah FK, Chow PK, Goh BK.

HPB (Oxford). 2015 Oct 16. doi: 10.1111/hpb.12490. [Epub ahead of print] Review.

PMID:
26472490
36.

Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma.

Khor AY, Toh Y, Allen JC, Ng DC, Kao YH, Zhu G, Choo SP, Lo RH, Tay KH, Teo JY, Goh BK, Burgmans MC, Irani FG, Goh AS, Chow PK.

Hepatol Int. 2014 Jul;8(3):395-404. doi: 10.1007/s12072-014-9533-9. Epub 2014 Apr 5.

PMID:
26202641
37.

Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.

Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, Lim HY, Choo SP.

Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408. doi: 10.1007/s00280-015-2811-y. Epub 2015 Jun 24.

PMID:
26099969
38.

Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma.

Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH.

PLoS One. 2015 May 13;10(5):e0128058. doi: 10.1371/journal.pone.0128058. eCollection 2015. No abstract available.

39.

The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma.

Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH.

PLoS One. 2015 Apr 1;10(4):e0118658. doi: 10.1371/journal.pone.0118658. eCollection 2015. Erratum in: PLoS One. 2015;10(5):e0128058.

40.

Do elderly patients benefit from enrollment into Phase I Trials?

Tai WM, Lim C, Ahmad A, Ong WS, Choo SP, Lim WT, Tan EH, Kanesvaran R, Tan DS.

J Geriatr Oncol. 2015 May;6(3):241-8. doi: 10.1016/j.jgo.2015.02.003. Epub 2015 Mar 14.

PMID:
25779876
41.

Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.

Wang J, Wang X, Zhao M, Choo SP, Ong SJ, Ong SY, Chong SS, Teo YY, Lee CG.

PLoS One. 2014 Nov 5;9(11):e111694. doi: 10.1371/journal.pone.0111694. eCollection 2014.

42.

Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.

Chow PK, Poon DY, Khin MW, Singh H, Han HS, Goh AS, Choo SP, Lai HK, Lo RH, Tay KH, Lim TG, Gandhi M, Tan SB, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group.

PLoS One. 2014 Mar 10;9(3):e90909. doi: 10.1371/journal.pone.0090909. eCollection 2014.

43.

Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.

Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT.

Nat Genet. 2013 Dec;45(12):1474-8. doi: 10.1038/ng.2806. Epub 2013 Nov 3.

PMID:
24185513
44.

Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma.

Wang WW, Ang SF, Kumar R, Heah C, Utama A, Tania NP, Li H, Tan SH, Poo D, Choo SP, Chow WC, Tan CK, Toh HC.

PLoS One. 2013 Jul 18;8(7):e68904. doi: 10.1371/journal.pone.0068904. Print 2013.

45.

The evolving landscape of therapeutic drug development for hepatocellular carcinoma.

Chong DQ, Tan IB, Choo SP, Toh HC.

Contemp Clin Trials. 2013 Nov;36(2):605-15. doi: 10.1016/j.cct.2013.03.013. Epub 2013 Apr 13.

PMID:
23591326
46.

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.

Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BY, Kopp MV, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei YJ, Galimi F, McCaffery I, Pan Y, Loberg R, Cottrell S, Choo SP.

Ann Oncol. 2013 Jul;24(7):1777-85. doi: 10.1093/annonc/mdt057. Epub 2013 Mar 19.

PMID:
23510984
47.

Localized gastrointestinal stromal tumor of the rectum: An uncommon primary site with prominent disease and treatment-related morbidities.

Farid M, Lee MJ, Chew MH, Ong WS, Sairi AN, Foo KF, Choo SP, Koo WH, Ong S, Koh PK, Quek R.

Mol Clin Oncol. 2013 Jan;1(1):190-194. Epub 2012 Sep 19.

48.

A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.

Choo SP, Chowbay B, Ng QS, Thng CH, Lim C, Hartono S, Koh TS, Huynh H, Poon D, Ang MK, Chang S, Toh HC.

Eur J Cancer. 2013 Mar;49(5):999-1008. doi: 10.1016/j.ejca.2012.11.008. Epub 2012 Dec 19.

PMID:
23265712
49.

Increased α-fetoprotein likely induced by complementary health products.

Chua C, Tan IB, Choo SP, Toh HC.

J Clin Oncol. 2013 Feb 20;31(6):e80-2. doi: 10.1200/JCO.2012.42.5009. Epub 2012 Nov 26. No abstract available.

PMID:
23182988
50.

A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.

Kim YH, Muro K, Yasui H, Chen JS, Ryu MH, Park SH, Chu KM, Choo SP, Sanchez T, DelaCruz C, Mukhopadhyay P, Lainas I, Li CP.

Cancer Chemother Pharmacol. 2012 Oct;70(4):583-90. Epub 2012 Aug 12.

Supplemental Content

Support Center